ALB Stock Analysis: Albemarle | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 12.316m USD | 12M Return: 16.9% | US0126531013 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 273M
Qual. Beats: 0
Rev. Trend: -82.8%
Qual. Beats: 3
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Albemarle Corporation is a global specialty chemicals company headquartered in Charlotte, North Carolina, founded in 1887. It operates through three business segments: Energy Storage (lithium compounds such as carbonate, hydroxide, and chloride used in batteries for consumer electronics and electric vehicles, as well as power grids and solar panels), Specialties (bromine-based products, lithium specialties, cesium, zirconium, barium, and titanium products serving industries like fire safety, pharmaceuticals, and pyrotechnics), and Ketjen (clean fuels technologies and catalysts for hydroprocessing, fluidized catalytic cracking, and alkylation).
The company serves a diverse customer base spanning grid storage, automotive, aerospace, conventional energy, electronics, construction, agriculture, pharmaceuticals, and medical devices. Classified within the Materials sector under the Specialty Chemicals sub-industry, Albemarle is a large-cap U.S. listed company that has been publicly traded on the NYSE since 1994, making it one of the longest-established players in the global lithium and bromine value chains.
- Lithium prices decline on oversupply, pressuring Energy Storage margins
- EV demand growth slows, weighing on lithium volume outlook
- IRA tax credits boost domestic lithium production economics
| Net Income: 224.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 9.57 > 1.0 |
| NWC/Revenue: 34.75% < 20% (prev 51.18%; Δ -16.43% < -1%) |
| CFO/TA 0.11 > 3% & CFO 1.80b > Net Income 224.2m |
| Net Debt (457.2m) to EBITDA (1.23b): 0.37 < 3 |
| Current Ratio: 2.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (136.2m) vs 12m ago 15.76% < -2% |
| Gross Margin: 23.89% > 18% (prev 7.72%; Δ 16.17% > 0.5%) |
| Asset Turnover: 35.59% > 50% (prev 28.88%; Δ 6.72% > 0%) |
| Interest Coverage Ratio: 2.53 > 6 (EBIT TTM 437.4m / Interest Expense TTM 172.8m) |
| A: 0.13 (Total Current Assets 3.94b - Total Current Liabilities 1.89b) / Total Assets 15.9b |
| B: 0.33 (Retained Earnings 5.23b / Total Assets 15.9b) |
| C: 0.03 (EBIT TTM 437.4m / Avg Total Assets 16.6b) |
| D: 1.90 (Book Value of Equity 10.3b / Total Liabilities 5.41b) |
| Altman-Z'' = 4.09 = AA |
| DSRI: 0.70 (Receivables 727.7m/879.7m, Revenue 5.91b/4.99b) |
| GMI: 0.32 (GM 7.72% / 23.89%) |
| AQI: 1.08 (AQ_t 0.22 / AQ_t-1 0.20) |
| SGI: 1.18 (Revenue 5.91b / 4.99b) |
| TATA: -0.10 (NI 224.2m - CFO 1.80b) / TA 15.9b) |
| Beneish M = -3.72 (Cap -4..+1) = AAA |
As of October 07, 2026, the stock is trading at USD 106.35 with a total of 1,496,984 shares traded. Over the past week, the price has changed by -1.18%, over one month by -17.64%, over three months by -20.25% and over the past year by +16.89%.
Current recommended Stop Loss: 100.20 (which is 5.8% or 1.4 ATR below the current price).
Albemarle has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy ALB.
- StrongBuy: 10
- Buy: 3
- Hold: 9
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 169.8 | 59.7% |
P/E Trailing = 386.5555
P/E Forward = 11.4286
P/S = 2.0847
P/B = 1.6654
P/EG = 0.7941
Revenue TTM = 5.91b USD
EBIT TTM = 437.4m USD
EBITDA TTM = 1.23b USD
Long Term Debt = 1.80b USD (from longTermDebt, last quarter)
Short Term Debt = 78.9m USD (from shortTermDebt, last quarter)
Debt = 2.09b USD (from shortLongTermDebtTotal, last quarter) + Leases 103.1m
Net Debt = 457.2m USD (calculated: Debt 2.09b - CCE 1.63b)
Enterprise Value = 12.8b USD (12.3b + Debt 2.09b - CCE 1.63b)
Interest Coverage Ratio = 2.53 (Ebit TTM 437.4m / Interest Expense TTM 172.8m)
EV/FCF = 9.52x (Enterprise Value 12.8b / FCF TTM 1.34b)
FCF Yield = 10.51% (FCF TTM 1.34b / Enterprise Value 12.8b)
FCF Margin = 22.72% (FCF TTM 1.34b / Revenue TTM 5.91b)
Net Margin = 3.79% (Net Income TTM 224.2m / Revenue TTM 5.91b)
Gross Margin = 23.89% ((Revenue TTM 5.91b - Cost of Revenue TTM 4.50b) / Revenue TTM)
Gross Margin QoQ = 33.86% (prev 35.06%)
Tobins Q-Ratio = 0.80 (Enterprise Value 12.8b / Total Assets 15.9b)
Interest Expense / Debt = 8.27% (Interest Expense 172.8m / Debt 2.09b)
Taxrate = 33.24% (90.7m / 272.9m)
NOPAT = 292.0m (EBIT 437.4m * (1 - 33.24%))
Current Ratio = 2.09 (Total Current Assets 3.94b / Total Current Liabilities 1.89b)
Debt / Equity = 0.20 (Debt 2.09b / totalStockholderEquity, last quarter 10.3b)
Debt / EBITDA = 0.37 (Net Debt 457.2m / EBITDA 1.23b)
Debt / FCF = 0.34 (Net Debt 457.2m / FCF TTM 1.34b)
Total Stockholder Equity = 9.91b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.35% (Net Income 224.2m / Total Assets 15.9b)
RoE = 2.26% (Net Income TTM 224.2m / Total Stockholder Equity 9.91b)
RoCE = 3.73% (EBIT 437.4m / Capital Employed (Equity 9.91b + L.T.Debt 1.80b))
RoIC = 2.12% (NOPAT 292.0m / Invested Capital 13.8b)
WACC = 12.15% (E(12.3b)/V(14.4b) * Re(13.28%) + D(2.09b)/V(14.4b) * Rd(8.27%) * (1-Tc(0.33)))
Discount Rate = 13.28% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 55.52 | Cagr: 6.81%
[DCF] Terminal Value 63.33% ; FCFF base≈1.34b ; Y1≈1.35b ; Y5≈1.43b
[DCF] Fair Price = 110.4 (EV 13.5b - Net Debt 457.2m = Equity 13.0b / Shares 118.0m; r=12.15% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.46 | # QB: 0
Revenue Correlation: -82.80 | Revenue CAGR: -21.19% | SUE: 1.24 | # QB: 3
EPS current Quarter (2026-09-30): EPS=2.58 | Chg30d=+3.15% | Revisions=+0% | Analysts=15
EPS current Year (2026-12-31): EPS=11.57 | Chg30d=+0.06% | Revisions=-42% | GrowthEPS=+1564.9% | GrowthRev=+19.2%
EPS next Year (2027-12-31): EPS=11.00 | Chg30d=-2.61% | Revisions=-39% | GrowthEPS=-4.9% | GrowthRev=+1.7%
[Analyst] Revisions Ratio: -44% (up=8, down=23)